atogepant
Brand: Qulipta
Prototype: ubrogepant
Drug Class: CGRP receptor antagonist (gepant)
Drug Family: antimigraine
Subclass: small-molecule CGRP receptor antagonist
Organ Systems: cns
Mechanism of Action
Daily oral CGRP receptor antagonist for migraine prevention; blocks CGRP-mediated trigeminal sensitization chronically to reduce migraine frequency. First oral preventive migraine treatment with CGRP mechanism.
CGRP receptor
Indications
- preventive treatment of episodic migraine (adults)
- preventive treatment of chronic migraine (adults — FDA approved 2023)
Contraindications
- concurrent strong CYP3A4 inhibitors (reduce dose)
- concurrent strong CYP3A4 inducers (increase dose)
Adverse Effects
Common
- nausea
- constipation
- fatigue
Serious
- hepatotoxicity (rare)
- hypersensitivity reactions
Pharmacokinetics (ADME)
| Absorption | oral; food has no significant effect |
| Distribution | protein binding ~99% |
| Metabolism | primarily CYP3A4 |
| Excretion | fecal (~42%) and renal (~42%) |
| Half-life | 11 hours |
| Onset | preventive effect over weeks to months |
| Peak | 1-2 hours |
| Duration | 24 hours per dose |
| Protein Binding | 99% |
| Vd | not well characterized |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| strong CYP3A4 inhibitors | increase atogepant levels; use lower dose (10 mg) | major |
| strong CYP3A4 inducers | decrease atogepant levels; use higher dose (60 mg) | major |
Nursing Considerations
- Once-daily preventive treatment; distinguish clearly from acute migraine treatments.
- CYP3A4 interactions require dose adjustment; verify all concurrent medications.
- Constipation is a class-wide CGRP antagonist effect; encourage adequate hydration and dietary fiber.
- Approved for both episodic and chronic migraine prevention; review migraine frequency to confirm appropriate indication.
Clinical Pearls
- Atogepant is the first daily oral CGRP receptor antagonist for migraine prevention, offering an oral alternative to the injectable anti-CGRP monoclonal antibodies.
- The CGRP pathway is now the foundation of migraine pharmacology for both acute (triptans, gepants, ditans) and preventive (gepants, monoclonal antibodies) treatment — a landmark in migraine-targeted drug development.
Safety Profile
Pregnancy avoid
Lactation avoid
Renal Adjustment Required
Hepatic Adjustment Required
TDM Not required
Guideline Update pending
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.